Overall Survival Dan Disease-Free Survival Pasien Kanker Payudara Di Rsud Dr. Moewardi Surakarta: Analisis Retrospektif

The survival of breast cancer patients is influenced by clinical, biomolecular, and therapeutic characteristics. Evaluating these factors is essential for understanding their relationship with overall survival (OS) and disease-free survival (DFS). This study aimed to analyze OS and DFS, as well as the factors influencing these outcomes, in breast cancer patients at Dr. Moewardi Regional General Hospital, Surakarta. A retrospective study was conducted using the medical records of 100 patients. Survival analysis was performed using the Kaplan–Meier method, and differences between survival curves were tested using the log-rank test. The results showed a mean OS of 31.29 months and a mean DFS of 33.76 months. Clinical factors—including axillary lymph node status, tumor size, stage, and histopathology—did not show a significant association with OS; however, the stage was significantly associated with DFS (p=0.013). Biomolecular factors—such as lymphovascular invasion, estrogen receptor status, progesterone receptor status, immunohistochemical profile, and molecular subtype—did not show a significant association with either OS or DFS. The Ki-67 proliferation index was not significantly associated with OS but showed a significant association with DFS (p=0.002). Therapeutic factors—including chemotherapy, radiotherapy, hormonal therapy, and targeted therapy—did not show a significant association with OS. Similarly, chemotherapy, radiotherapy, and targeted therapy showed no significant association with DFS; the relationship between hormonal therapy and DFS could not be tested, as no patients were recorded as having received this treatment. These findings should be interpreted with caution, given the sample size, imbalanced group distribution, and the inherent limitations of a retrospective design. Further research with larger sample sizes, longer follow-up periods, and multivariable analysis is required to confirm independent prognostic factors and improve the precision of survival estimates.